Outcomes of Primary Vitrectomy for Rhegmatogenous Retinal Detachment With No Postoperative Positioning.

Autor:	Babel A; Boonshoft School of Medicine, Dayton, OH, USA.; Erie Retinal Surgery & Erie Retina Research, Erie, PA, USA., Xu K; Retina Consultants of Georgia, Augusta, GA, USA., Chin EK; Retina Consultants of Southern California, Redlands, CA, USA.; Loma Linda Eye Institute, Veterans Affair Hospital, Loma Linda, CA, USA., Almeida D; Erie Retinal Surgery & Erie Retina Research, Erie, PA, USA.
Jazyk:	angličtina
Zdroj:	Journal of vitreoretinal diseases [J Vitreoretin Dis] 2024 Mar 14; Vol. 8 (3), pp. 253-256. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024).
DOI:	10.1177/24741264241237022
Abstrakt:	Purpose: To evaluate the anatomic and visual outcomes of primary vitrectomy for rhegmatogenous retinal detachment (RRD) repair using no amount of postoperative prone positioning to clarify the role of face-down posturing for RRD reattachment. Methods: This retrospective consecutive interventional case series comprised patients who had primary vitrectomy for RRD repair. The surgical outcomes, single-surgery anatomic success rate, and postoperative best-corrected visual acuity (BCVA) were assessed. The primary objective was to evaluate the anatomic and visual outcomes of vitrectomy RRD reattachment using no postoperative prone positioning. Results: This study comprised 116 eyes of 116 patients. Single-surgery anatomic success was achieved in 112 (96.5%) of 116 eyes. The single-surgery anatomic success rate was 100% in phakic patients (n = 56) and 93% in pseudophakic patients (n = 60), with both groups having an improvement in the mean BCVA. Conclusions: Primary vitrectomy with no postoperative prone positioning is a successful surgical intervention for RRD repair. The anatomic closure rate in this study is one of the highest reported in the literature and involved a large number of macula-off RRDs, with minimal complications and a significant improvement in BCVA, primarily using 14% perfluoropropane for gas tamponade. Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Almeida: Acelyrin, Alcon, Alimera Sciences, Allergan/Abbvie, Bausch + Lomb, Bayer, Boehringer Ingelheim, Citrus Therapeutics, Clinical Trials Network, EyePoint Pharmaceuticals, Inc, Genentech, Gyroscope Therapeutics, Novartos, Ocugen, Opthea, Regeneron, RegenXBio, Roche, Samsara Vision, Spherix Consulting Group. Dr. Chin: Alimera Sciences, Allergan, Bayer, Citrus Therapeutics, Genentech, Hexal AG/Sandoz Inc, Iveric Bio, Kodiak Sciences, Novartis, Opthea, Regeneron. None of the other author(s) declared potential conflicts of interest with respect to the research, authorship, and/or publication of the article. (© The Author(s) 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu